Proportion of time spent in the Start Room or Avoidance Room or showing a behaviour (Stimulus Contact) presented across stimuli and separately for piglets and gilts. by Sara Hintze (3216885)

Subjects:

Conceptual framework to guide the study. by Resham B. Khatri (10949429)

Subjects:

Wear morphology: (a) UT, (b) SP1, (c) SP2, and (d) SP3. by Huashen Guan (20454677)

Subjects:

Residual stress of various samples: (a) surface residual stress and (b) residual stress in the depth direction. by Huashen Guan (20454677)

Subjects:

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

Subjects:

General procedure for the synthesis of B. by Xueqin lu (22250795)

Subjects:

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects:

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Subjects:

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects:

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Subjects:

DIO Mice Liver Staining. by Xueqin lu (22250795)

Subjects:

Risk of bias summary. by Duc Tran Quang (20564967)

“…The observed decrease in body weight could be partially attributed to factors influencing energy balance, as evidenced by the significantly lower mean calorie intake at the end of the intervention (1694.71 kcal/day, 95% CI: 1498.57–1890.85) compared to the baseline intake (2000.64 kcal/day, 95% CI: 1830–2172.98), despite the absence of intentional efforts to restrict energy intake by the participants. …”

Criteria for study selection. by Duc Tran Quang (20564967)

“…The observed decrease in body weight could be partially attributed to factors influencing energy balance, as evidenced by the significantly lower mean calorie intake at the end of the intervention (1694.71 kcal/day, 95% CI: 1498.57–1890.85) compared to the baseline intake (2000.64 kcal/day, 95% CI: 1830–2172.98), despite the absence of intentional efforts to restrict energy intake by the participants. …”

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Subjects:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects:

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Subjects:

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

Subjects: